Why Jim Cramer Is 'Excited' About Johnson & Johnson
Johnson & Johnson (JNJ) reported earnings on Tuesday.
Johnson & Johnson said adjusted earnings came in at $1.86 cents per share, down 1.1% from the same period last year but four cents ahead of the Street consensus forecast. Group revenues, Johnson & Johnson said, rose 8.3% to $22.5 billion, again beating estimates of a $21.67 billion tally.
"Our notable full year performance reflects the continued confidence from patients, physicians, customers and consumers in our life-enhancing products and medicines, particularly throughout the COVID-19 pandemic," said CEO Alex Gorsky.
The company added that it will be releasing an update on its COVID-19 vaccine Phase 3 study 'soon.'
Everything Jim Cramer Is Watching in the Market Tuesday